Kemény Kata Kira, Seres-Bokor Adrienn, Barna Tamara, Mirdamadi Mohsen, Gáspár Róbert, Surányi Andrea, Ducza Eszter
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Hungary.
Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School, University of Szeged, 6720, Szeged, Hungary.
Heliyon. 2024 Sep 3;10(17):e37329. doi: 10.1016/j.heliyon.2024.e37329. eCollection 2024 Sep 15.
Aquaporins (AQPs) are involved in the process of implantation, regulate myometrial contractions and cervical ripening, and maintain appropriate placental functioning. The molecular mechanism of these functions is not fully understood. Our study aimed to investigate the physiological significance of AQP5 during pregnancy and to determine the cooperation between the adrenergic system and the AQP5 in uterine contraction in the late-pregnant rat uterus. After administering AQP5 siRNA intraperitoneally to Sprague-Dawley rats, the length of the gestational period was determined and the changes in uterine contractions were measured in an isolated organ bath system. Pharmacological influence on AQP5 expression and uterine contraction was investigated by treatment with terbutaline (10 mg/kg, subcutaneously) and doxazosin (5 mg/kg, orally) ; and mercuric chloride (HgCl), . Moreover, the levels of cAMP response element binding protein (CREB) were measured in the uterus by an ELISA kit. The gestational period became shorter, AQP5 expression significantly decreased and rat uterus contraction increased after AQP5 siRNA treatment compared to the control. Treatment with terbutaline significantly increased AQP5 mRNA and protein expression after 30 min and continuously reduced it until 90 min, whereas doxazosin treatment did not significantly alter AQP5 expression. Treatment with the AQP5 antagonist HgCl increased spontaneous uterus contraction and decreased norepinephrine-induced uterus contraction with decreasing AQP5 expression in pregnant rat uterus. Moreover, the tocolytic effect through the adrenergic system was amplified in the presence of an AQP5 antagonist, presumably via the changes in cAMP level. In conclusion, our findings elucidate the collaborative role of aquaporin 5 (AQP5) and adrenergic systems in the regulation of uterine contractions in late-pregnant rats. Our findings suggest this may be a good starting point for developing a new tocolytic therapy.
水通道蛋白(AQPs)参与着床过程,调节子宫肌层收缩和宫颈成熟,并维持胎盘的正常功能。这些功能的分子机制尚未完全明确。我们的研究旨在探讨AQP5在孕期的生理意义,并确定肾上腺素能系统与AQP5在妊娠晚期大鼠子宫收缩中的协同作用。对Sprague-Dawley大鼠腹腔注射AQP5 siRNA后,测定妊娠期长度,并在离体器官浴系统中测量子宫收缩的变化。通过用特布他林(10mg/kg,皮下注射)、多沙唑嗪(5mg/kg,口服)和氯化汞(HgCl)处理,研究其对AQP5表达和子宫收缩的药理学影响。此外,用ELISA试剂盒测定子宫中cAMP反应元件结合蛋白(CREB)的水平。与对照组相比,AQP5 siRNA处理后妊娠期缩短,AQP5表达显著降低,大鼠子宫收缩增强。特布他林处理30分钟后显著增加AQP5 mRNA和蛋白表达,并持续降低至90分钟,而多沙唑嗪处理未显著改变AQP5表达。用AQP5拮抗剂HgCl处理可增加妊娠大鼠子宫的自发收缩,并降低去甲肾上腺素诱导的子宫收缩,同时降低AQP5表达。此外,在存在AQP5拮抗剂的情况下,通过肾上腺素能系统的保胎作用增强,推测是通过cAMP水平的变化实现的。总之,我们的研究结果阐明了水通道蛋白5(AQP5)和肾上腺素能系统在妊娠晚期大鼠子宫收缩调节中的协同作用。我们的研究结果表明,这可能是开发新的保胎疗法的一个良好起点。